In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Left atrial strain predicts cardiovascular events in chronic systolic heart failure patients treated with cardiac resynchronization therapy.

Session Poster session 2

Speaker Luca Rossi

Congress : EHRA 2018

  • Topic : heart failure
  • Sub-topic : Resynchronization Therapy
  • Session type : Poster Session
  • FP Number : P815

Authors : L Rossi (Piacenza,IT), A Malagoli (Piacenza,IT), A Zanni (Piacenza,IT), C Sticozzi (Piacenza,IT), G Villani (Piacenza,IT)

Authors:
L Rossi1 , A Malagoli1 , A Zanni1 , C Sticozzi1 , G Villani1 , 1Guglielmo da Saliceto Hospital - Piacenza - Italy ,

Citation:
European Heart Journal Supplements ( 2018 ) 20 ( Supplement 1 ), i148

Introduction 
Heart failure (HF) is a major cause of death, and it has a poor prognosis despite the significant reduction in mortality achieved in clinical trials. Left atrial (LA) function represents powerful outcome predictor in patients with HF, because closely related to left ventricular diastolic dysfunction. Two-dimensional speckle tracking (2DST) is an echocardiographic tool that enable the quantification of longitudinal myocardial LA deformation dynamics.

The purpose of the present study was to evaluate the usefulness of 2DST analysis of LA function to predict cardiovascular outcomes in outpatients affected by chronic HF with reduced ejection fraction implanted with cardiac resynchronization device (CRT). 

Methods 
We prospectively enrolled consecutive outpatients with chronic HF and previous CRT implantation. Transthoracic echocardiography was performed at the basal visit: left ventricular volumes, left atrial volumes and peak atrial longitudinal strain (global PALS) were measured. The development of MACE (major adverse cardiovascular events) during follow up was evaluated as a composite endpoint defined as congestive HF + nonfatal myocardial infarction  + stroke + cardiovascular mortality.

Results
146 patients (mean age 67±11, 81% male) met eligibility criteria. Almost all patients presented LA dilation and LA difunction. During a median follow-up of 48±11 months MACE occurred in 61 (42%) patients.
In a multivariable model global PALS [HR: 0.97 (95% CI: 0.94 – 0.99), p =0.04], left ventricular ejection fraction [HR: 0.94 (95% CI: 0.91 – 0.97), p<0.01] and renal function [HR: 0.98 (95% CI: 0.98 – 0.99), p =0.01] were independent predictors of an adverse outcome.

Moreover, during follow-up 33 patients (23%) died for cardiovascular  events.  It was confirmed that global PALS [HR: 0.96 (95% CI: 0.93 – 0.99), p = 0.02], left ventricular ejection fraction [HR: 0.96 (95% CI: 0.93 – 1.00), p = 0.03] and renal function [HR: 0.98 (95% CI: 0.97– 0.99), p < 0.01] were independent predictors of cardiovascular mortality.

Conclusion 
In chronic systolic heart failure population treated with CRT, left atrial longitudinal deformation analysis derived from two-dimensional speckle-tracking echocardiography independently correlates with cardiovascular outcome.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are